TNPSC Thervupettagam

New Treatment for Crohn’s Disease

January 1 , 2025 21 days 213 0
  • About 10 million people globally live with the inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease.
  • Mirikizumab is a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis.
  • Researchers revealed that, the long-term efficacy and safety of Mirikizumab for not only ulcerative colitis, but also Crohn’s disease.
  • Inflammation from ulcerative colitis and Crohn’s disease can lead to disruptive symptoms.

499 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Categories

PrevNext
SuMoTuWeThFrSa
   1234
567891011
12131415161718
19202122232425
262728293031 
Top